CA1256638A - Polymer and its production - Google Patents

Polymer and its production

Info

Publication number
CA1256638A
CA1256638A CA000486142A CA486142A CA1256638A CA 1256638 A CA1256638 A CA 1256638A CA 000486142 A CA000486142 A CA 000486142A CA 486142 A CA486142 A CA 486142A CA 1256638 A CA1256638 A CA 1256638A
Authority
CA
Canada
Prior art keywords
acid
weight
lactic acid
copolymer
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000486142A
Other languages
French (fr)
Inventor
Motoaki Tanaka
Yasuaki Ogawa
Tsutomu Miyagawa
Toshio Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Fujifilm Wako Pure Chemical Corp
Original Assignee
Wako Pure Chemical Industries Ltd
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15266918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1256638(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP59140356A external-priority patent/JPH0678425B2/en
Application filed by Wako Pure Chemical Industries Ltd, Takeda Chemical Industries Ltd filed Critical Wako Pure Chemical Industries Ltd
Application granted granted Critical
Publication of CA1256638A publication Critical patent/CA1256638A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

POLYMER AND ITS PRODUCTION

Abstract of the Disclosure A polymer or copolymer of lactic acid and/or glycolic acid which has a weight-average molecular weight of not less than about 5,000 and a dispersity of about 1.5 to 2 is advantageously used as a biodegradable polymer or copolymer for medical preparation.

Description

63~

The present invention relates to a polymer of lactic acid or glycolic acid, a copolymer of lactic acid and glycolic acid and a method for producing the polymer or the copolymer by a polycondensation reaction in the presence of a solid inorganic acid catalyst.
In recent years, degradable polymers have attracted a good deal of attention, for example, as readily degradable poly-mers serving to mitigate environmental pollution and also as biodegradable polymers for medical use.
A method for producing a copolymer of lactic acid and glycolic acid is disclosed in UOS. Patent No. 4,273,920. In this Patent, it is stated that a copolymer substantially free of poly-merization catalyst is obtained by reacting lactic acid with glycolic acid in the presence of a readily removable strong acid ion-exchange resin, and removing the resin therefrom.
However, the copolymers produced by the above- described method all exhibit a dispersity in molecular weight as high as nearly 3 or more, an~ in use, give great complexity in fac~ors involving solubility and other aspects, thus presenting major problems in controlling such factors. Therefore, they cannot be said to be very favorable, when they are used, for example, as a biodegradable polymer for medical use. In addition, this method allows the strong acid ion exchange resin being used as a poly-merization catalyst to deteriorate due to heat during a polycon-densation reaction under heating and to get dissolved in the resulting copolymer, thereby contributing to the development of coloration oE the copolymer. Furthermore, it is difficult to eliminate such coloration, and it is practically impossible to remove such coloration completely, and the coloration shows that the catalyst, i.e. the strong acid ion-exchange resin, cannot be completely removed. Such coloration not only diminishes value as an article of commerce but also is undesirable by virtue of i~s impurities.
In view of such circumstances, the present inventors conducted repeatedly intensive research, and found a method for 3~

~5~i63~

producing a polymer of lactlc acid or glycolic acid and a copoly-mer of lactic acid and glycolic acid, which are effective and substantially free from the above-mentioned disad~antages. Based on this finding and a further research, the present inventors have completed the present invention.
The present invention is directed to:
(1) A polymer or copolymer of lactic acid and/or glycolic acid, which has a weight-average molecular weight of not less than about 5,000 and a dispersity of about 1.5 to 2, and (2~ A method for producing a polymer or copolymer of lactic acid and/or glycolic acid comprising subjecting lactic acid and/or glycolic acid to a polycondensation reaction, with a solid inorganic acid catalyst as a polycondensation catalyst.
In the method of the present invention, lactic acid and/or glycolic acid are/is employed, as the starting materials, in the form of crystals, powders or granules as such, or in the form of an aqueous solution. The concentration of the solution is arbitrarily selected, preferably as high as possihle, and more preferably not lower than about 85 ~ (w/w).
As the lactic acid and/or glycolic acid starting material, low molecular polymers of lactic acid or glycolic acid or low molecular copolymers of lactic acid and glycolic acid may be employed in the present method.
Such low molecular polymers of ]actic acid or glycolic acid, may be oligomers (e.g. dimers, trimers, etc.) of lactic acid, or glycolic acid.
One SUCh low molecular polymer or copolymer starting material is produced by sub~ecting lactic acid and/or glycolic acid to a polycondensation reaction in the absence of a catalyst under for example about 100 to 150C/350 to 30 mmHg ~or more than about 2 hours, normally about 2 to 10 hours, more preferably while increasing the temperature and reducing the pressure stepwise from about 105C/350 mmHg to 150C/30 mmHg for about 5 to 6 hours, to remove water. In this process, a low molecular polymer or co-polymer of molecular weight of about 2000 to 4000 is obtained.

~256638 Furthermore~ as the low molecular copolymers, there are mentioned, or example, ones which are obtainable by processes described in Kogyo Kagaku Zasshi (Journal of the Chemical Society of Japan), vol. 68, pp. 983-986 (1965), i.e. lactic acid and gly-colic acid are reacted in a normal atmospheric pressure and in the absence of a catalyst at 202C for 6 hours, or U.S. Patent No. ~,362,511, i.e. lactic acid and glycolic acid are reacted at a temperature of 200~C holding the mixture at that temperature for a period of about 2 hours and subsequently continuing the heating for another period of about 2 hour under vacuum.
The ratio of lactic acid to glycolic acid in the copoly-mer, when the object compound is a copolymer of these compounds, is preferably about 50 to 95 weight % of lactic acid and about 50 to 5 weight % of glycolic acid, preferably about 60 to 95 weight of lactic acid and about 40 to 5 weight ~ of glycolic acid, more preferably about 60 to ~5 weight % of lactic acid and about ~0 to 15 weight % oE glycolic acid. The ratio is more preferably about 75+2 mol ~ of lactic acid and about 25+2 mol ~ of glycolic acid~
A solvent may be employed, when the starting material is in crystal, powder or granule form. Such solvents are, for example, water, methanol, ethanol and acetone.
The solid inorganic acid catalyst inclu3es acid clay, activated clay, bentonite, kaolin, talc, aluminum silicate, mag-nesium silicate, alumina bolia, and silicic acid. These can all be used, either solely or as a mixture and each may be employed as such or after being washed with, for example, hydrochloric acid at a concentration of 5 to 20 ~, to remove metal ions, if necessary.
The amount of the solid inorganic acid catalyst used in the present method is normally about 0.5 to 30 ~ w/w, preferably abo~t 1 to 20 ~ w/w, based on the total amount of lactic acid and glycolic acid. The catalyst can be used in one or several portions.
The catalyst may be added to the reaction system during the reaction.
The method is preferably carried out with heating and ~:256~;31~

under reduced pressure. The heating is carried out by heating reaction system at about 150 to 250~C, preferably about 150 to 200C. The reduced pressure is normally about 30 to 1 mmHg, preferably about 10 to 1 mmHg. The reaction time of the present polycondensation reaction is normally not less than about 10 hours, preferably about 10 to 150 hours, more preferably about 10 to 100 hours~
When lactic acid and/or glycolic acid are/is employed as the starting materials, the following conditions are preferred:
Heating under reduced pressure at about 100 to 150C/350 to 30 mmHg for not less than about 2 hours, normally about 2 to 10 hours, for example, for about 5 to 6 hours while increasing the temperature and the degree of reduced pressure stepwise to about 105C/350 mmHg to 150C/30 mmHg, to remove water, followed by a dehydration polycondensation reaction at about 150 to 200C/10 to 1 mmHg for not less than about 10 hours, normally up to about 100 hours may be adequate.
When a low molecular polymer or copolymer is employed as starting material, preferred reaction conditions are as follows-A dehydration polycondensation reaction is carried out at about150 to 200C/10 to 1 mmHg for not less than about 10 hours, nor-mally up to about 100 hours may be adequate.
After termina-tion of the reaction, the objective polymer or copolymer is readily obtained by removing the used solid in-organic acid catalyst. The solid acid catalyst oE the present invention can easily be removed for example by filtration with suction using ordinary qualitative filter paper. Mere hot filtra-tion of the reaction solution or filtration after dissolution of the polymer or copolymer in a suitable solvent such as methylene chloride, dichloroethane, chloroform or acetone, (in an amount of about lO-times that of the polymer or copolymer), is sufficient.
No subsequent treatment is required, either in the former case in which the reaction solution is filtered as such and the solvent is concentrated or distilled off, or in the latter case in which the reaction solution is filtered after being dissolved in a solvent.

~s~

If desired, a conventional separation may be used, for example, by pouring the filtered reaction solution, either directly or in the form of a concentrated Eiltrate where a solvent is used, into a large amount of a precipitant. If required, further purification may be carried out by reprecipitation, etc.
The present invention provides a polymer or copolymer consi~ting of lactic acid and/or glycolic acid units having a weight-average molecular weight oE not less than about 5,000, preferably about 5,000 to 30,000, and having a dispersity of about 1.5 to 2. Furthermore, the polymer or copolymer is colorless to almost white.
As the polymer or copolymer oE the present invention has a low degree of dispersity, the distribution of the molecular weight of the polymer or copolymer is not wide.
Furthermore, as the solid inorganic acid catalyst is insoluble in the polymer or copolymer and in a solven'c, the catalyst is substantially completely removed from the reaction product and the resulting polymer or copolymer is substantially free of catalyst discoloration.
The polymer or copolymer obtained can be utilized as a base for drug preparation. For example, by incorporating steroid hormones, peptide hormones or anti-tumor agents, etc. into them for embedded or microcapsule type controlled release preparations or by preparing fine particles containing an ~256 E;3~

anti-tumor agent to process into a therapeutlc agent for embolization.
The ~periment Examples and Examples are described below to illustrate the present invention in more detail.
Experimen _Example 1 To 160 g (1.5 mole as lactic acid) of a 85 %
aqueous solution of lactic acid was added 6.8 g of a solid acid catalyst, and heating under reduced pressure was carried out for 6 hours under the stepwise varyins conditions of lO0 to 150C/350 to 30 mmHg under a stream of nitrogen gas to remove the resulting water.
Subsequently, 6.8 g of the solid acid catalyst was added additionally, followed by a dehydration polycondensation reaction at 175C/5 mmHg for 72 hours.
Shown in Table 1 is the relationship between reaction time and weight-average molecular weight attained and its dispersity in the production of lactic acid polymers.
Also shown in Table l for the purpose of comparison are the results obtained with Dowe~ 50 (a cross-linked polystyrene resin, Dow Chemical Co., U.S.A.), a strongly acidic ion-exchange resin being commercially available, which was used as a polymerization reaction.
The weight-average molecular weight and dispersity (d;spersity = weiaht-averaae molecular weignt) in th~
number-aver2ge molecular we1ght present specification were measured by gel permea~ion chromatography utilizing the standard polystyrene with the known molecular weight.

* Trade Mark ~L~S~

Table 1 Type of polyme~ization catalysts and molecular weight attained and its dispersity Catalyst: Alumin~m Actlvated Acid clay silicate clay Dowex 50W
Added amount (1) 6.8 g 6.8 g 6.8 g 6.8 gAdded amount (2) 6.8 g 6.8 g 6.8 ~ 6.8 g . _ _ . _ . _ _ . . _ _ ~ . _ . . _ _ 12 hours of 6,200 5,000 reaction time (1.71) (1.63) 24 hours o~ 8,90011,200 8,800 s,ioo reaction time (1.88) (1.66) (1.61) (2.43) 36 hours of ï6,60015,600 12,700 1_,400 reaction time (1.72) (1.6~) ' (1.62) (2.63) 48 hours of 19,100 16,700 1~,900 reaction time _ (1.65) (1.50) (2.80) 60 hours oE 26,50022,500 19,900 17,800 reaction time (1.73) (1.66) (1.67) (2.81) i2 hours of 29,300*25,800 23,700 20,200 reaction time (1.77) (1.6c) (1.81) (2.80) Appearance ofAlmostAlmost Almost Dark brown (thë
the polymer**whitewhite white color deepens _ with time) - -- -- _ . ._ Note: * ; Reaction time of nearly 65 hours.
** ; Each of the polymers obtained after the respective reactlon time was dissolvea in methylene chloride of the volume four tlmes that of the polvmer, and the solution was filtered using Toyo'Filter Paper No. 131 [?oyo Roshl Co., Ltd., Japan] to remove the c-_al st, and then concentrated to distill o f the solvent; the resulting polymers were examined in accordance with JIS K 8004-2 (namely, a~out 3 g of the specimen is taken on a watch glass, which is placed on a sheet of white paper and examined.).
In the Table 1, the added amount (1) of catalyst and the added amount (2) of catalyst deno-te an initially added amount of catalyst and an amount of catalyst additionally added at the time of the polycondensation ' Trade Mark ~2S6~i313 s reaction at 175C/5 mmHg after removal of water, respectively while the reaction time means that at 175C/5 mmHg. In the table, the parenthesized value beneath the molecular weight attained indicates a dispersity.
As is clear from Table 1, the present invention can permit readily the production of high molecular weight polymer with a weight-average molecular weight of not less than about 5,000 being almost free from polymerization catalyst, whereby the resulting polymers show that colored appearance is hardly observed and the polymers have dispersity of not more than 2, with the polymerization reaction rate being evidently promoted by the addition of the catalyst.
Ex~eriment Exam~le 2 After 160 g (1.5 mole) of a 85 % aqueous solution of lactic acid and 38 g tO.5 mole) of glycolic acid were mixed, 8.7 g of a solid acid catalyst was added to the mixture, and heating under reduced pressure was carried out at 100 to 150C/350 to 30 mmHg under a stream of nitrogen gas for 6 hours to remove the distilled water.
Subsequently, 8.7 g of the solid acid catalyst was adaed additionally, followed by a dehydration condensation reaction at 175C/6 to 5 mmHg for 72 hours.
Shown in Table 2 is the relationship between reaction time and weight-average molecular weight attained in the production of copolymers of lactic acid and glycolic acid.
Also, shown in Table 2 for the purpose of comparison are the results obtained with a strongly acidic ion-exchange resin (Dowex*50W) which was used as a polymerization catalyst.

* Trade Mark ~5~;~3~

g Table 2:
Type of polymerlzation catalysts and molecular weights attained Catalyst: Type Aluminum Activated Acid clay silicate clayDowex 50W
.
Added amount (1) 8.7 g 8.7 g 8.7 g 8.7 g Added amount (2) 8.7 g 8.7 g 8.7 g 8.7 g 12 hours of 5,100 reaction time (1.72) 24 hours of 12,600 11,700 10,200 10,500 10 reaction time (1.72) (1.72) _ (1.69) (2 47) 36 hours of 18,600 17,800 16,100 1~,400 reaction time (1.73) (1.74) (1.65) (2.44) 48 hours of 22,900 22,000 20,400 18,900 reaction time (1.65) (1.64) (1.64) (2.46) 60 hours of 25,400 25,800 22,800 22,200 reaction ti~e (1.68) (1.68) (1.63) _ (2.47) 15 72 hours of 27,900 28,600 26,000 25,300 reac-tion ti~e (1.76) (1.66) (1.63) (2.76) Almost AlmostAlmost Dark brown (the the polymer* white white white color deepens Note: ~ ; Each of the polymers obtained after the respective reaction time was dissolved in methylene chloride of the volume :Eour times that of the polymer, and the solution was filtered using Toyo Filter Paper No. 131 to remove the catalyst, and then, concentrated to distill off the solvent; the resulting polymers were examined in accordance with JIS K 8004-2 (namely, about 3 g of the specimen is taken on a watch glass, which is placed on a sheet of white paper and examined.).
In the Table 2, the added amount (1) of catalyst and the added amount (2) of catalyst denote an initially added amount of catalyst and an amount of catalyst additionally added at the time of the polycondensation reaction at 175C/5 mmHg after removal of water, respectively, while the reaction time means tha-t at 175C/5 mmHg. In the Table 2, the parenthesized value ~LZ5~;63~

. - 10 -beneath the molecular weiqht attained indicates a dispersity.
As is clear from Table 2, the present invention can - permit readily the production or high molecular weight lactic acid-glycolic acid copolymers with a weight-average molecular weight of not less than about 5,000 being almost free from polymerization catalyst, whereby the resulting copolymers show that colored appearance is hardly observed, and all has dispersity as small as not more than 2, with the polymerization reaction rate being evidently promoted by the additlon of the catalyst.
Furthemore, analysis of nuclear magnetic resonance spectrometry on said resulting copolymer of the present invention in CDC13 solution indicates the followin~
composition of lactic acid and glycolic acid.

~ ~ 2~i3~

Copolymer ratio of the present copolymer mol %
(weight %) Catalist Aluminum Activated Reaction~~- _ Acid Clay time ~ _ _ slllcate Clay 12 hours _ _ _ 75.5:24.5 (79.3:20.7) ._ __ _ ___ _ .. __ 75 ~25 75 ~25 75.5:24.5 24 hours l(78.8:21.2) (78.8:21.2) (79.3:20.7) ... _ .__ I _ ._ ', 75 :25 75 :25 75 :25 36 hours (78.8:21.2) (78 8:21.2) (78.8:21.2) ._ ,,_ , __ 75 :25 76 :24 75 :25 48 hours (78.8:21.2) (79.7:20.3) (78.8:2102) _ _ _ _ _ !
75.5:24.5 75.5:24.5 76 :24 60 hours (79.3:20.7) (79.3:20.7) (79.7:20.3) . _ .
75.5:24.5 75.5:24.5 75.5:24.5 1 72 hours (79.3:20.7) (79.3:20.7) (79.3 20.7)1 ~:~S~63~

Example 1 Placed in a four-necked flask equipped with a thermometer, condenser and inlet tube for nitrogen gas were 160 g of a 85 % aqueous solution of lactic acid and 13.6 g of acid clay, and heating under reduced pressure was carried out under a stream of nitrogen gas over the period of 6 hours, while increasing the internal temperature and the degree of internal reduced pressure stepwise from 105C and 350 mmHg to 150C and 30 mm~g, and then the resulting water was removed. Successively, heating was conducted under reduced pressure of 3 mmHg and at the internal temperature of 175C for 50 hours.
The reaction solution was cooled to room temperature, and 400 m~ of methylene chloride was added to it, followed by stirring to a solution. Then, the acid clay was removed by fil-tration using Toyo Filter Paper No 131, and the filtrate was concentrated to dryness to give 100 g of an almost colorless polyer, which has a weight-average molecular weight of 22,000 and a dispersity of 1.75.
In order to determine the remaining catalyst in the resultina copolymer, a specimen of the copolymer was weighed out onto a dish of platinum and subjected to a fusing treatment with sodium carbonate, and then aluminum and silicon were determined colorimetrically by ~S~631~

application of the aluminon method and molybdenum blue method, with the result that neither of the metals was detected, leading to the conclusion that there was no contamination of the catalyst observed.
Example 2 A reaction was carried out in the manner of Example 1, except that 27.2 g of aluminum silicate was used as a catalyst, and there was obtained 92 g of an almost colorless polymer, which has a weight-average molecular weight of 21,900 and a dispersity of 1.70. The similar results were obtained when kaolin and talc were used in place of aluminum silicate as a catalyst.
In order to determine the remaining catalysts in the resulting copolymers, detection of the remaining catalysts was carried out in the manner of Example l, with the result that there was no contamination of catalysts observed.
Example 3 In the manner of Example 1, 160 g of a 85 % aqueous solution of lactic acid was used, but 6.8 g of activated clay was charged in place of acid clay, whereupon after removal of the resulting water, a heating reaction was conducted at the internal pressure of 5 mmHg and at the internal temperature of 185C for 96 hours to give 90 g of an almost white polymer. The resulting polymer has a weight-average molecular weight of 29,600 and a dis-persity of 1.85.
In order to determine the remaining catalyst in the resulting polymer, detection of the remaining catalyst was carried out in the manner of Example l, with the result that there was no contamination of catalyst observed.
Example 4 A reaction was conducted in the manner of Example l, except that 160 g of a 85 % a~ueous solution of lactic ~256~3g~

acid, 38 g of glycolic acid and 17.4 g of activated clay were used, and there was obtained 122 g of an almost white copolymer, which has a weight-average molecular weight of 20,100 and a dispersity of 1.70, and shows a copolymerization composition of lactic acid and glycolic acid of 76 mol % : 24 mol % (79.7 weight % : 20.3 weight %).
In order to determine the xemaining catalyst in the resulting copolymer, detection of the remaining catalyst was carried out in the manner of Example 1, with the result that there was no contamination of catalyst observed.
Example 5 Charged were 191 g of a 85 ~ aqueous solution of lactic acid, 17.5 g of glycolic acid and 9 g of acid clay, and after removal of the distilled water, a heating reaction was carried out at the internal pressure of 3 mmHg and at the internal temperature of 170C for 96 hours to give 130 g of an almost white copolymer. The resulting copolymer has a weight-average molecular weight of 28,100 and a dispersity of 1.73, and a copolymeriza-tion composition of lactic acid and glycolic acid of 89 mol % : 11 mol %~90.9 weight ~ : 9.1 weight %).
The similar results were obtained, when the similar reaction was carried out with aluminum silicate, bentonite and kaolin being used as a catalyst instead.
In order to determined the remaining catalysts in the resulting copolymers, detection of the remaining catalysts was conducted in the manner of Example 1, with the result that there was no contamination of catalysts observed.
Example 6 146 g of a 93 % aqueous solution of lactic acid and 38 g of glycolic acid was used, a heating reaction was ~2S6Ei3~

conducted at the temperature of 202C for 6 hours, whereby a copolymer with a welght-average molecular weight of 2,700 and a composition of lactic acid and glycolic acid of 75 mol % : 25 mol % was obtained.
Weighed in the same polymerization apparatus as usedin Example 1 were 100 g of this copolymer and 10 g of aeid clay, and heating was earried out under redueed pressure of 5 mmHg at internal temperature of 180C for 50 hours.
The reaction solution was eooled to room temperature, and 500 ml of methylene ehloride was added to it, followed by stirring to a solution. Then, the acid clay was removed by filtration using Toyo Filter Paper No. 131 and the filtrate was concentrated to dryness to give 82 g of an almost colorless polymer, which showed a weight-average moleeular weight of 23,700 and a dispersity of 1~73, and a eopolymerization composition of laetie acid and glycolie acid of 75 mol % : 25 mol %(78.~ weight ~: 21.2 weight ~).
In order to determine the remaining eatalyst in the resulting polymer, deteetion of the remaining catalyst was carried out in the manner of Example 1, with the result that there was no contamination of catalyst observed.
Example 7 A reaetion was eonducted in the manner of Example 6, exeept that 97 g of laetie acid dimer (Lactic acid lactate) and 54 g of glycolic acid dimer (Glycologlycolic acid) and 7.5 g of acid clay were used, and there was obtained 98 g of an almost white copolvmer, which has a weight-average molecular weight of 21,000 and a dis-persity of 1~ 75, and a copolymerization composition oflaetic aeid and glycolie acid of 59.5 mol % : 40.5 mol (64.6 weight % : 35.4 weight %).
In order to determine the remaining catalyst in the resulting copolymer, detection of the remaining catalyst was carried out in the manner of Example 1, with the result that there was no contaminatiOn of eatalyst observed.

Claims (19)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for producing a polymer of lactic acid or glycolic acid or a copolymer of lactic acid and glycolic acid, which comprises subjecting a member selected from the group con-sisting of lactic acid, glycolic acid or a combination thereof, to a polycondensation reaction with a solid inorganic acid cata-lyst as a polycondensation catalyst, wherein the solid inorganic acid catalyst is selected from the group consisting of acid clay, activated clay, bentonite, kaolin, talc, aluminium silicate, mag-nesium silicate, alumina bolia and silicic acid.
2. A method according to claim 1, wherein the weight-average molecular weight of the polymer or copolymer is not less than about 5,000 and the dispersity of the polymer or copolymer is about 1.5 to 2.
3. A method according to claim 1, wherein the weight-average molecular weight of the polymer or copolymer is about 5,000 to 30,000 and its dispersity is about 1.5 to 2.
4. A method according to claim 1, 2 or 3, wherein lactic acid is polymerized to obtain a polymer of lactic acid.
5. A method according to claim 1, 2 or 3, wherein a combin-ation of lactic acid and glycolic acid is polymerized to obtain a copolymer of lactic acid and glycolic acid.
6. A method according to claim 1, 2 or 3, wherein a com-bination of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 50 to 95 weight % of lactic acid and about 50 to 5 weight % of glycolic acid.
7. A method according to claim 1, 2 or 3, wherein a combin-ation of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 60 to 95 weight % of lactic acid and about 40 to 5 weight % of glycolic acid.
8. A method according to claim 1, 2 or 3, wherein a combin-ation of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 60 to 85 weight % of lactic acid and about 40 to 15 weight % of glycolic acid.
9. A method according to claim 1, 2 or 3, wherein a combin-ation of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 75?2 mol % of lactic acid and about 25?2 mol % of glycolic acid.
10. A method according to claim 1, 2 or 3, wherein the solid inorganic acid catalyst is kaolin.
11. A method according to claim 1, 2 or 3, wherein the solid inorganic acid catalyst is one selected from the group consisting of acid clay, activated clay, kaolin, bentonite and aluminium silicate.
12. A method according to claim 1, 2 or 3, wherein the solid inorganic acid catalyst is acid clay.
13. A method according to claim 1, 2 or 3, wherein the solid inorganic acid catalyst is activated clay.
14. A method according to claim 1, 2 or 3, wherein the solid inorganic acid catalyst is alauminium silicate.
15. A method according to claim 1, 2 or 3, wherein a combination of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 50 to 95 weight % of lactic acid and about 50 to 5 weight % of glycolic acid and the solid inorganic acid catalyst is selected from the group consisting of acid clay, activated clay, bentonite, kaolin, talc, aluminium silicate, magnesium silicate, alumina bolia and silicic acid.
16. A method according to claim 1, 2 or 3, wherein a combination of lactic acid and glycolic acid is polymerized to obtain a copolymer having a ratio of about 60 to 85 weight % of lactic acid and about 40 to 15 weight % of glycolic acid and the solid inorganic acid catalyst is one selected from the group consisting of acid clay, activated clay, kaolin, bentonite and aluminium silicate.
17. A homopolymer lactic acid or glycolic acid, which has a weight-average molecular weight of not less than about 5,000 and a dispersity of about 1.5 to 2.
18. A polymer according to claim 17, wherein the weight-average molecular weight is about 5,000 to 30,000.
19. A polymer according to claim 17 or 18, which is a homopolymer of lactic acid.
CA000486142A 1984-07-06 1985-06-28 Polymer and its production Expired CA1256638A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP140356/1984 1984-07-06
JP59140356A JPH0678425B2 (en) 1984-07-06 1984-07-06 New polymer manufacturing method

Publications (1)

Publication Number Publication Date
CA1256638A true CA1256638A (en) 1989-06-27

Family

ID=15266918

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000486142A Expired CA1256638A (en) 1984-07-06 1985-06-28 Polymer and its production
CA000486283A Expired CA1236641A (en) 1984-07-06 1985-06-28 Copolymer of lactic acid and glycolic acid and method for producing same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA000486283A Expired CA1236641A (en) 1984-07-06 1985-06-28 Copolymer of lactic acid and glycolic acid and method for producing same

Country Status (8)

Country Link
US (2) US4677191A (en)
EP (2) EP0172636B2 (en)
AT (2) ATE39935T1 (en)
BG (1) BG61520B2 (en)
CA (2) CA1256638A (en)
DE (2) DE3567471D1 (en)
HK (1) HK19592A (en)
SG (1) SG108191G (en)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
DE3720806C2 (en) * 1986-07-03 1997-08-21 Clariant Finance Bvi Ltd Use of a stabilizer in peroxide bleaching processes
US4758435A (en) * 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
DE3641692A1 (en) * 1986-12-06 1988-06-09 Boehringer Ingelheim Kg CATALYST-FREE RESORBABLE HOMOPOLYMERS AND COPOLYMERS
DE3710175A1 (en) * 1987-02-12 1988-08-25 Hoechst Ag MULTI-PIECE IMPLANTABLE MEDICINE PREPARATION WITH LONG-TERM EFFECT
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
EP0428620B1 (en) * 1988-08-08 1999-03-03 Biopak Technology, Ltd. A method of plasticizing lactide polymers.
AU634723B2 (en) * 1988-08-08 1993-03-04 Biopak Technology, Ltd. Degradable thermoplastic from lactides
US5250584A (en) * 1988-08-31 1993-10-05 G-C Dental Industrial Corp. Periodontium-regenerative materials
JP2714454B2 (en) * 1988-11-07 1998-02-16 三井東圧化学株式会社 Method for producing bioabsorbable polyester
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
FR2654337B1 (en) * 1989-11-15 1994-08-05 Roussel Uclaf NOVEL BIODEGRADABLE INJECTABLE MICROSPHERES PREPARATION METHOD AND INJECTABLE SUSPENSIONS CONTAINING THEM.
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4005415C2 (en) * 1990-02-21 1996-04-11 Boehringer Ingelheim Kg Process for the preparation of polyesters based on hydroxycarboxylic acids
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
NO302481B1 (en) 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for an extended release preparation, as well as an extended release preparation
IT1249045B (en) * 1991-02-21 1995-02-11 Himont Inc SOLID STATE SYNTHESIS PROCESS OF LACTIC ACID POLYMERS AND PRODUCTS SO OBTAINED
US6005067A (en) * 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5294469A (en) * 1992-06-17 1994-03-15 Mitsui Toatsu Chemicals, Incorporated Industrial woven fabric and composite sheet comprising same
US5758053A (en) * 1992-07-22 1998-05-26 Hitachi, Ltd. Fault handling and recovery for system having plural processors
DK0615555T3 (en) * 1992-10-02 2001-07-09 Cargill Inc Textile material of melt-stable lactide polymer and process for preparation thereof
ES2123668T3 (en) * 1992-10-02 1999-01-16 Cargill Inc PAPER WHICH HAS A STABLE CAST LACTIDE POLYMER COATING AND PROCEDURE FOR ITS MANUFACTURE.
US6005068A (en) * 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
US5643595A (en) * 1992-11-24 1997-07-01 Alkermes Controlled Therapeutics Inc. Ii Growth promoters for animals
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
NZ276088A (en) 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
WO1997008220A1 (en) * 1995-08-29 1997-03-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxy carboxylic acid
SE505146C2 (en) * 1995-10-19 1997-06-30 Biogram Ab Particles for delayed release
EP0823448A4 (en) * 1996-02-23 1998-08-12 Kyowa Hakko Kogyo Kk Process for the preparation of polyhydroxycarboxylic acid
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
DE60019638T2 (en) 1999-12-10 2005-09-22 Equipolymers Gmbh CATALYST SYSTEMS FOR POLYCONDENSATION REACTIONS
US6960626B2 (en) * 2000-01-21 2005-11-01 Cyclics Corporation Intimate physical mixtures containing macrocyclic polyester oligomer and filler
PT1310517E (en) 2000-08-07 2006-05-31 Wako Pure Chem Ind Ltd LACTICAL ACID POLYMER AND PROCESS FOR ITS PRODUCTION
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
CA2418347C (en) * 2000-08-16 2010-03-30 Tyco Healthcare Group Lp High consistency absorbable polymeric resin
US7767781B2 (en) 2000-09-01 2010-08-03 Cyclics Corporation Preparation of low-acid polyalkylene terephthalate and preparation of macrocyclic polyester oligomer therefrom
US7750109B2 (en) 2000-09-01 2010-07-06 Cyclics Corporation Use of a residual oligomer recyclate in the production of macrocyclic polyester oligomer
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp Zero-order prolonged release coaxial implants
ATE305931T1 (en) 2001-06-27 2005-10-15 Cyclics Corp ISOLATION, FORMULATION AND FORMULATION OF MACROCYCLIC OLIGOESTERS
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
JP2003192773A (en) * 2001-12-26 2003-07-09 Mitsui Chemicals Inc Bioabsorptive polyhydroxy carboxylic acid and its production method
US6849600B2 (en) * 2002-03-25 2005-02-01 The Regents Of The University Of California, Berkeley Corticotropin-releasing hormone analogs
KR100684682B1 (en) * 2002-09-24 2007-02-22 아사히 가세이 케미칼즈 가부시키가이샤 Glycolic Acid Copolymer and Method for Production Thereof
EP1440992A1 (en) * 2003-01-21 2004-07-28 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Catalyst composition for (co)polymerisation of lactide and glycolide
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
CA2915574C (en) 2003-07-18 2017-02-07 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
DE112005000965T5 (en) * 2004-04-28 2007-03-22 Keio University Depolymerization process for ester bond-containing polymers in the backbone and process for preparing ester linkage polymers in the backbone of the depolymerization product
ES2357243T3 (en) * 2004-05-21 2011-04-20 Micro Therapeutics, Inc. METAL SPIRALS INTERLATED WITH POLYMERS OR BIOLOGICAL OR BIODEGRADABLE OR SYNTHETIC FIBERS FOR THE EMBOLIZATION OF A BODY CAVITY.
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
ATE448737T1 (en) 2004-09-22 2009-12-15 Dendron Gmbh DEVICE FOR IMPLANTING MICROWL COILS
DE102005019782A1 (en) * 2005-04-28 2006-11-09 Dendron Gmbh Device for implantation of occlusion coils with internal securing means
EP1716847B1 (en) * 2005-04-28 2008-01-02 Nipro Corporation Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
EP2078197B1 (en) 2006-11-01 2016-03-23 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
CA2671670C (en) * 2006-12-18 2015-02-10 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
KR20100015520A (en) 2007-03-13 2010-02-12 마이크로 테라퓨틱스 인코포레이티드 An implant including a coil and a stretch-resistant member
EP2326304A2 (en) 2008-07-17 2011-06-01 Merial Limited Methods for enhancing the stability of polyorthoesters and their formulations
CA2741030A1 (en) 2008-10-20 2010-04-29 Marvin C. Gershengorn Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
EP2364082A4 (en) 2008-10-21 2012-06-06 Oregon Health And Sciences University Naphthamides as anticancer agents
CN101445595B (en) * 2008-12-26 2011-01-19 上海新上化高分子材料有限公司 Poly glycolide lactide (PGLA), preparation method and application thereof
WO2011094426A1 (en) 2010-01-29 2011-08-04 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Caspase inhibitors
AU2011237421B2 (en) 2010-04-08 2016-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inverse agonists and neutral antagonists for the TSH receptor
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
US9446048B2 (en) 2011-03-17 2016-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins
CN102329269B (en) * 2011-06-30 2013-07-17 南京大学 Synthesis of bionic creatininium chloride and catalytic polycondensation method for synthesizing high-molecular-weight polylactic acid
CN102295765B (en) 2011-06-30 2012-11-28 南京大学 Copolycondensation synthesized polylactic acid-glycollic acid catalyzed by biomass creatinine
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
WO2013106847A1 (en) 2012-01-13 2013-07-18 Oregon Health & Science University Compounds, compositions and associated methods comprising 3-aryl quinolines
SG11201408171SA (en) 2012-06-08 2015-01-29 Univ Pittsburgh Fbxo3 inhibitors
IN2015DN03733A (en) 2012-11-13 2015-09-18 Us Health
WO2014093702A1 (en) 2012-12-12 2014-06-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hiv therapeutics and methods of making and using same
CN105611927A (en) 2013-05-16 2016-05-25 美国政府(由卫生和人类服务部的部长所代表) Compounds for inhibiting drug-resistant strains of HIV-1 integrase
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
CA2948349C (en) 2014-05-09 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
EP4070795A1 (en) 2014-08-25 2022-10-12 Salk Institute for Biological Studies Novel ulk1 inhibitors and methods using same
EP3189067B1 (en) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
EP3242661B1 (en) 2015-01-05 2019-08-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Myc g-quadruplex stabilizing small molecules and their use
WO2016134292A1 (en) 2015-02-20 2016-08-25 Oregon Health & Science University Derivatives of sobetirome
US20180273485A1 (en) 2015-06-04 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Cannabinoid receptor mediating compounds
EP3347047A1 (en) 2015-09-09 2018-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
EP3423448A1 (en) 2016-03-04 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
RS62408B1 (en) 2016-05-18 2021-10-29 Univ Oregon Health & Science Derivatives of sobetirome
EP3471828A1 (en) 2016-06-16 2019-04-24 Acies Bio d.o.o. Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
EP3675921A1 (en) 2017-08-31 2020-07-08 Evonik Corporation Improved resorbable polymer purification process
WO2019118803A1 (en) 2017-12-14 2019-06-20 The United States Of America, As Represented By The Secretary,Department Of Health And Human Services Chemical entities for lytic activation of kshv and therapeutic targeting of viral enzymes/proteins
JP7359460B2 (en) 2018-03-29 2023-10-11 エレックス バイオテック, インコーポレイテッド Compounds for the treatment of cardiac arrhythmias and heart failure
AU2019349424B2 (en) 2018-09-25 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
US11667606B2 (en) 2019-03-01 2023-06-06 Autobahn Therapeutics, Inc. Thyromimetics
WO2020185695A1 (en) 2019-03-11 2020-09-17 Oregon State University Analogues and derivatives of cephalotaxine and methods for making and using the compounds
WO2022261296A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same
WO2023059867A1 (en) 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease
WO2023146771A1 (en) 2022-01-25 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gingerenone a prodrugs as senotherapeutics and methods of use
WO2023177568A1 (en) 2022-03-14 2023-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor modulating compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1995970A (en) * 1931-04-04 1935-03-26 Du Pont Polymeric lactide resin
US2362511A (en) * 1939-11-21 1944-11-14 Du Pont Modified glycolide resins
US2438208A (en) * 1943-07-10 1948-03-23 Us Agriculture Continuous process of converting lactic acid to polylactic acid
US2683136A (en) * 1950-10-25 1954-07-06 Du Pont Copolymers of hydroxyacetic acid with other alcohol acids
US2703316A (en) * 1951-06-05 1955-03-01 Du Pont Polymers of high melting lactide
US2758987A (en) * 1952-06-05 1956-08-14 Du Pont Optically active homopolymers containing but one antipodal species of an alpha-monohydroxy monocarboxylic acid
US3531561A (en) * 1965-04-20 1970-09-29 Ethicon Inc Suture preparation
US3498957A (en) * 1965-09-14 1970-03-03 Ethicon Inc Polymerization of cyclic carboxylic esters in the presense of a nonpolymerizable ester plasticizer
US3468853A (en) * 1966-06-15 1969-09-23 American Cyanamid Co Process of polymerizing a glycolide
BE758156R (en) * 1970-05-13 1971-04-28 Ethicon Inc ABSORBABLE SUTURE ELEMENT AND ITS
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions

Also Published As

Publication number Publication date
DE3567471D1 (en) 1989-02-16
US4683288A (en) 1987-07-28
US4677191A (en) 1987-06-30
EP0172636B2 (en) 1992-11-11
EP0171907B1 (en) 1989-01-11
ATE39936T1 (en) 1989-01-15
ATE39935T1 (en) 1989-01-15
DE3567470D1 (en) 1989-02-16
EP0171907A1 (en) 1986-02-19
SG108191G (en) 1992-06-12
EP0172636A1 (en) 1986-02-26
CA1236641A (en) 1988-05-10
BG61520B2 (en) 1997-10-31
EP0172636B1 (en) 1989-01-11
HK19592A (en) 1992-03-20
EP0171907B2 (en) 1994-08-10

Similar Documents

Publication Publication Date Title
CA1256638A (en) Polymer and its production
JPS6128521A (en) Novel polymer and its production
JP2000514855A (en) Derived rhodamine dyes and their copolymers
EP0692510A1 (en) Preparation of anhydride copolymers
JPS63264610A (en) Gel type chelate resin and method of removing polyhydric alkali earth or heavy metal cation from solution
JP2001522899A (en) Biodegradable anionic polymer derived from amino acid L-tyrosine
Memon et al. Syntheses and binding properties of polymeric calix [4] crown-4
US6111137A (en) Purification process of lactic acid
US5183853A (en) Articles of a new crystalline form of syndiotactic styrene polymer
JPH07109587A (en) Polymer for water treatment and its production
JPS61111326A (en) Novel polymer and its production
EP0449505B1 (en) Fluorescent polymers and ingredients therefor
JP3168263B2 (en) Novel polymer and drug using the same
US4066522A (en) Process for the production of high molecular weight acrylamide polymers
JPH0873517A (en) Method for isolating isobutylene polymer
Tomono et al. Synthesis and esterolytic reactions of linear and cross‐linked asymmetric imidazole‐containing polymers
KR100370591B1 (en) Superporous Poly(allylamine) Hydrogels And The Process For The Preparation Thereof
US3780097A (en) Purification of alkalimetal salts of aromatic carboxylic acids
JP2758945B2 (en) Method for producing polyhydroxybenzophenones
JPH0551362A (en) Method for purifying self-polymerizable monomer
US5103057A (en) Acrylamide copolymers containing (meth)acrylamide benzene dicarboxylic units
Eisenbach et al. Synthesis of poly (ethylene‐d4oxide) with unimodal and narrow molecular weight distribution
JPH0267239A (en) Purification of 2,2-bis(4-hydroxyphenyl)hexafluoropropane
SU919326A1 (en) Carborane-containing oligophenylenes for making structural materials
JP2537174B2 (en) Cross-linking method

Legal Events

Date Code Title Description
MKEX Expiry